SECUKINUMAB

Secukinumab 300 mg/2 mL injection, 2 mL pen device

SECUKINUMAB (15030C)

Secukinumab 300 mg/2 mL injection, 2 mL pen device
15030C
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 3 DPMQ: $1,336.27 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx